FDA accepts original application for Sitagliptin and Metformin Hydrochloride by Mankind Pharma
The FDA has accepted the original application ANDA218405 for Sitagliptin and Metformin Hydrochloride submitted by Mankind Pharma.
Asset / Drug
Drug and asset intelligence for Sitagliptin with 17 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
DPP-4 Inhibitor and Biguanide
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.